iiinova — where your digital self keeps evolving

insitro @insitro.bsky.social · 08/09/2026

We're thrilled to welcome Hideo Makimura as CMO, a pivotal step as we advance our therapeutic programs toward the clinic. We could not imagine a better partner to help us translate the insights generated by our platform into meaningful medicines for patients. www.insitro.com/news/insitro...

000

insitro @insitro.bsky.social · 03/08/2026

insitro this summer: Seoul, Boston, Rome, Palo Alto - and still going. Jennitte Stevens at the Bioprocessing Summit Aug. 10.

000

insitro @insitro.bsky.social · 11/06/2026

We’re at GRC Bioorganic Chemistry this week w/ a talk on high-throughput chemistry for ML and a poster on next-gen DEL architectures. #GRC2026 #DrugDiscovery

000

insitro @insitro.bsky.social · 08/06/2026

Today we shared preclinical data from our CTRO-1013 program at #ADA2026 demonstrating that liver-targeted silencing of IRS1 significantly reduced injury-associated biomarkers. Effects appear partly independent of liver fat reductions. (1/4)

100

insitro @insitro.bsky.social · 10/05/2026

4 conferences. 3 continents. 2 weeks. We shared science demonstrating our Virtual Human™ Physical AI platforms: PETRI/ContrastiveBiVI (ICLR); 2.5D OCT model + AMD GWAS (ARVO); ~100× TherML screening (Keystone); & our ALS program with BMS (Target ALS). → Up next: BIOMED Israel in Tel Aviv on 5/12.

010

insitro @insitro.bsky.social · 01/05/2026

Looking forward to rEVOLUTION, where insitro CEO Daphne Koller will join “AI in Drug Discovery: Separating Signal from Science Fiction.” She’ll share insitro’s perspective on building AI-native drug discovery grounded in human data, biology, and experiment. revolution.wsgrevents.com

020

insitro @insitro.bsky.social · 30/04/2026

“I think that we’re already seeing an incredible set of advancements in leveraging these methods for biology discovery.” insitro CEO Daphne Koller in @thewashingtonpost.bsky.social on AI + biology reshaping drug discovery. Read more: www.washingtonpost.com/wp-intellige...

washingtonpost.com

AI & Tech brief: Daphne Koller on AI-powered drug discovery

Plus, China’s dominance in clinical trials is worrying lawmakers

000

insitro @insitro.bsky.social · 27/04/2026

insitro is excited to return to the Milken Institute Global Conference. On May 3, CFO/CBO Mary Rozenman joins Alex Azar, Jake Becraft, Robert Nelsen & Sung Hee Choe for a discussion on sustaining global leadership in biomedical innovation.

100

insitro @insitro.bsky.social · 23/03/2026

insitro is proud to deepen our work in ALS with the expansion of our strategic collaboration with @bms-news.bsky.social and the nomination of two additional therapeutic targets discovered through insitro’s AI-driven Virtual Human™ platform. Read our press release: www.insitro.com/news/insitro...

111

insitro @insitro.bsky.social · 26/02/2026

We announced Joe Hand as insitro’s Chief People Officer. Joe brings a wealth of experience scaling life sciences organizations. As our AI & biology platform expands & our pipeline advances, Joe will lead our global people strategy to support our next phase of growth. www.insitro.com/news/insitro...

000

insitro @insitro.bsky.social · 02/02/2026

insitro’s David Lloyd reported the first-ever genome-wide association study of brown adipose tissue & a differentiated target w/ anti-obesity effects, the modulation of which reduced body weight 15% & fat mass 25% in preclinical models while preserving lean tissue. www.insitro.com/news/insitro...

000

insitro @insitro.bsky.social · 12/01/2026

insitro acquired CombinAbleAI & launched TherML™, completing a unified, modality-agnostic AI platform for therapeutic design across small molecules, biologics, & oligonucleotides, optimizing potency & developability from the start. 🔗 www.insitro.com/news/combina... 🔗 www.insitro.com/news/introdu...

000

insitro @insitro.bsky.social · 06/01/2026

insitro will present at #JPM26. CEO Daphne Koller will share progress across our AI-enabled discovery engine & programs advancing toward the clinic, w/ additional participation from our leadership team throughout the week. www.insitro.com/news/insitro...

010

insitro @insitro.bsky.social · 16/12/2025

New research in Nature Communications validates insitro’s POSH platform for mapping gene function using pooled CRISPR & self-supervised ML. By preserving rich cellular morphology, POSH reveals biology conventional approaches miss. 🔗 www.nature.com/articles/s41...

020

insitro @insitro.bsky.social · 05/12/2025

Samuel Sances will be at Intl. Symposium on ALS/MND Sunday to share work from collab. w/ @bristolmyerssquibb.bsky.social. #ML on 200+ patient-derived motor neuron lines, ID'd genes that rescue cellular function, reverse TDP-43 pathology & restore STMN2. symposium.mndassociation.org #DrugDiscovery

010

insitro @insitro.bsky.social · 03/12/2025

insitro is proud to welcome Stephen Hitchcock (ex-Takeda CSO) and Vijay Pande (VZVC co-founder, formerly on our Board) as scientific advisors, focused on translating AI-predicted targets into clinical drug candidates through our ChemML platform. www.insitro.com/news/insitro...

001

insitro @insitro.bsky.social · 20/11/2025

From genetic correlation to validated mechanism. Our #MASLD program (CTRO-1013) targeting IRS1 was named a Poster of Distinction at #AASLD2025. We used AI on multimodal data from 263K people to find the target, now validated & advancing to IND-enabling studies. www.insitro.com/news/reveali...

insitro.com

Revealing MASLD's Genetic Architecture: Machine Learning, Discovery, and the Path to IRS1 - insitro

Last week, insitro’s work on IRS1 was recognized as a Poster of Distinction at The Liver Meeting 2025. But the real story isn’t about recognition. It’s about learning to see...

000

insitro @insitro.bsky.social · 08/11/2025

Genomic data offers correlation in abundance. Causation requires experimental proof at every step. Join insitro at #AASLD2025. On Monday, 1pm, Poster 4013: learn how platform integration of AI, patient-derived biology & staged validation narrow the gap for MASLD therapeutics.

000

insitro @insitro.bsky.social · 14/10/2025

We extended our collaboration w/ @bristolmyerssquibb.bsky.social to advance our #ALS target into AI-enabled #drugdiscovery. The next phase is w/ our ChemML™ platform, turning discoveries➡️medicines w/ AI-driven modeling, medicinal chemistry, & structural biology. www.insitro.com/news/insitro...

000

insitro @insitro.bsky.social · 14/10/2025

We’re @ #ASHG to share our work that uses high-content phenotypic data, genetics & AI/ML to unblock new biology. @sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD @twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk

023

insitro @insitro.bsky.social · 09/09/2025

We’re excited to announce a new collaboration with @elilillyandcompany.bsky.social to build next-gen #machinelearning models for small molecule design. www.insitro.com/news/insitro...

120

insitro @insitro.bsky.social · 03/09/2025

Gabriel blends biology & ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read his Meet the insitrocyte below. arxiv.org/abs/2410.08938

010

insitro @insitro.bsky.social · 11/08/2025

7️⃣ years of using AI differently. That means looking where others don’t. . . or can’t.

110

insitro @insitro.bsky.social · 04/06/2025

@keystonesymposia.bsky.social’s joint conference is coming up! insitro’s Director Max Salick will present at “The Digital Era in Neurodegeneration & Neuroinflammation” to share recent research & technological advances on our POSH platform. Learn more: www.keystonesymposia.org/conferences/...

021

insitro @insitro.bsky.social · 18/03/2025

Today insitro announces an exciting new collaboration with insighteyehub.bsky.social at Moorfields Eye Hospital, London, through the development of a novel #AI foundation model to identify and to support #drugdiscovery. Learn more: www.businesswire.com/news/home/20...

032

insitro @insitro.bsky.social · 14/03/2025

Join insitro CEO & founder Daphne Koller at WIRED Health in London Tuesday, March 18 as she takes the keynote stage! 📣 Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI & data at scale.

010

insitro @insitro.bsky.social · 18/02/2025

Thanks to the SFBT for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both @elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...

010

insitro @insitro.bsky.social · 12/02/2025

Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work. Visit www.insitro.com/people/.

041

insitro @insitro.bsky.social · 11/02/2025

As our debut Bluesky post, we’re excited to share our new paper (first author Zachary McCaw) in HGG Advances on scrutinizing the practice of using a ratio trait (numerator / denominator) for GWAS. www.cell.com/hgg-advances...

052